The Wilmer Eye Institute's new Glaucoma Division chief discusses mentoring junior faculty, multicenter trials, and optic nerve regeneration.
News|Articles|August 11, 2026
A Multinational Real-World Evaluation of a Multi-Component Tear Substitute for Dry Eye Disease
Author(s)Piotr A. Woźniak, MD, PhD
Real-world insights into Artelac Complete, a preservative-free, multi-component tear substitute
Advertisement
Advertorial:
Real-world insights into Artelac Complete, a preservative-free, multi-component tear substitute. Dry eye disease is rarely confined to a single tear-film layer, yet many lubricants target only one. A multinational real-world evaluation examines how Artelac Complete, a multi-component tear substitute, performs in everyday practice.
Advertisement
Related to this article
At EURETINA 2026, Jordi Monés, MD, PhD, outlined the rationale for gene-agnostic optogenetic therapy MCO-010 to restore vision in Stargardt disease and geographic atrophy.
Eyes on September 2026: ESCRS insights, gene therapy wins, and the push to treat myopia as a disease
September was one of the busiest months of the year in eye care—From ESCRS to Eyecon
Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.
At EURETINA 2026, David Steel reviewed registry evidence on gas and silicone oil tamponades for retinal detachment repair and outlined novel tamponade agents in his Kreissig Award Lecture.
Host Deborah Ristvedt, DO, welcomes Dr. Mathews to discuss the relationships, passions, and intentional choices that have shaped her career as a cornea, cataract, and refractive surgeon, dry eye expert, and educator.
Sunir Garg, MD, FACS, previews DME and dry AMD data, free papers, and surgical sessions at AAO 2026.
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
4
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
5